Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLL By Ogkologos - February 25, 2025 717 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR FDA Approves Pembrolizumab for Advanced Oesophageal or Gastro-Oesophageal Carcinoma March 30, 2021 For Some Kids with Brain Cancer, Targeted Therapy is Better than... June 29, 2022 Breast Cancer Survivor And Teenage Son Hand-Sew Neck Pillows To Bring... August 15, 2019 Picture Showing A Realistic View Of A Woman’s Milk Ducts Goes... May 2, 2019 Load more HOT NEWS Dr. Alan S. Rabson, Long-Time NCI Deputy Director and Cancer Research... Treatment with a Hypomethylating Agent Can Activate or Up-regulate Oncogenes Will This Cancer Metastasize? Check Its “Stickiness” When Cancer Spreads to Bone, A Single Dose of Radiation Therapy...
